Literature DB >> 8150976

Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.

D J Biedenbach1, R N Jones.   

Abstract

Three members of the tribe Proteeae (Proteus vulgaris, Providencia rettgeri, and Providencia stuartii) were tested against five newer orally administered cephalosporins (cefdinir, cefprozil, cefuroxime, cefetamet, and loracarbef) by the disk diffusion and reference broth microdilution methods. One hundred strains of these organisms were tested to confirm the excessive interpretive error rates that previously had been noted for the disk diffusion test. The results indicate that the suggested disk diffusion breakpoints for cefetamet and cefuroxime were without serious interpretive errors. In contrast, loracarbef, cefdinir, and cefprozil results exceeded acceptable interpretive error rates, with very major (false-susceptible) errors of 4, 5, and 9% respectively. Loracarbef currently has a warning in the National Committee for Clinical Laboratory Standards table footnotes addressing this problem. We recommend including cefdinir and cefprozil in the list of compounds requiring this warning. In addition, MICs of cefazolin, cefaclor, and cephalothin were determined to establish whether a class MIC concept to predict susceptibility for these agents was possible. When the indole-positive Proteus strains are tested, cefazolin MICs can be used to predict MICs of all tested orally administered cephems (8 to 13% total errors, with only a 0 to 1% very major error.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150976      PMCID: PMC263078          DOI: 10.1128/jcm.32.2.559-562.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  5 in total

1.  Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

2.  Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

3.  Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Am J Clin Pathol       Date:  1983-08       Impact factor: 2.493

4.  Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.

Authors:  D J Biedenbach; R N Jones; M E Erwin
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

5.  Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

  5 in total
  1 in total

Review 1.  Classification, identification, and clinical significance of Proteus, Providencia, and Morganella.

Authors:  C M O'Hara; F W Brenner; J M Miller
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.